Please login to the form below

Not currently logged in
Email:
Password:

Alliance announces near-trebling profits

Alliance Pharma has announced a maiden dividend and strong first-half results, with sales up 34 per cent

Alliance Pharma has announced a maiden dividend and strong first-half results, with sales up 34 per cent. Deltacortril (prednisolone), its auto-immune drug, was the main driver of the sales growth, but there was a strong performance across the company's entire porfolio.

Alliance Pharma's chairman, Michael Gatenby said: "We are delighted to announce another set of strong results and the commencement of dividends. We now have a business generating sufficient profitability and cash flow to support both steady debt reductions and growing dividend payments."

Deltacortril was acquired by Alliance Pharma from Pfizer in 2006, and in August 2009 the company announced the acquisition of the prescription and OTC brand, Buccastem, as well as Timodine (on prescription only in the UK) from subsidiaries of Reckitt Benckiser. Gatenby confirmed that the company continues to seek acquisition opportunities to increase their portfolio.

10th September 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics